Linaprazan

Linaprazan

Clinical data
Other names	AZD-0865
Legal status
Legal status	Investigational
Identifiers
IUPAC name 8-[(2,6-Dimethylphenyl)methylamino]-N-(2-hydroxyethyl)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide
CAS Number	248919-64-4
PubChem CID	9951066
ChemSpider	8126677
UNII	E0OU4SC8DP
ChEMBL	ChEMBL497011
Chemical and physical data
Formula	C21H26N4O2
Molar mass	366.465 g·mol−1

Linaprazan is an experimental drug for the treatment of gastroesophageal reflux disease (GERD). Unlike the proton-pump inhibitors (PPIs) which are typically used to treat GERD, linaprazan is a potassium-competitive acid blocker (P-CAB). ^{[1] [2]} Linaprazan was developed by AstraZeneca, but it was not successful in clinical trials. ^[3]

The drug was then licensed to Cinclus Pharma, ^[4] which is now investigating linaprazan glurate, a prodrug of linaprazan which is expected to have a longer biological half-life than linaprazan itself. ^[4]

Chemical structure of linaprazan glurate

References

1. Rawla P, Sunkara T, Ofosu A, Gaduputi V (December 2018). "Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?". World Journal of Gastrointestinal Pharmacology and Therapeutics. 9 (7): 63–68. doi: 10.4292/wjgpt.v9.i7.63 . PMC   6305499 . PMID   30595950.
2. "Linaprazan". Inxight Drugs. National Center for Advancing Translational Sciences.
3. Tong A (4 March 2020). "Can reformulation of an AstraZeneca castoff rival Takeda's new heartburn drug? Here's a $26M bet on yes". endpts.com.
4. "Linaprazan glurate". Cinclus Pharma.